ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 804

Prolactin Induces Interferon Regulatory Factor 1 Activation and Histone H4 Hyperacetylation in Primary Monocytes Comparable to Changes Seen in Monocytes from Systemic Lupus Erythematosus Patients

Yiu Tak Leung1, Kathleen E. Sullivan2, Kelly Maurer3, Li Song4 and Lihua Shi3, 1Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA, 3Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, 4Allergy Immunology, Children's Hospital of Philadelphia, Philadelphia, PA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Epigenetics, histone acetylation and interferons, Lupus, SLE

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

: Epigenetic changes have been described in systemic lupus erythematosus (SLE) and offer a potential explanation for the chronicity of disease. We previously found a global increase in histone H4 acetylation (H4ac) in SLE monocytes and transcription factor motif analysis found 63% of genes with increased H4ac had potential interferon regulatory factor (IRF) 1 binding sites within the 5kb upstream region. We identified specific H4 lysine acetyl groups with significant hyperacetylation in SLE monocytes, as well as an imbalance in specific histone acetyltransferases (HATs) and histone deacetylases (HDACs) in favor of hyperacetylation. We then demonstrated that IRF1-overexpression can drive H4 hyperacetylation and showed IRF1 recruitment of HAT p300 to target genes with increased IRF1 binding and pathological expression in SLE monocytes.

IRF1 is highly inducible by prolactin, a hormone implicated in the pathogenesis of SLE: hyperprolactinemia has been reported in 15-33% of SLE patients as compared to 0.4-3% of controls. Prolactin upregulation of IRF1 can lead to H4ac in Nb2 T cells, representing a potential pathological pathway in SLE. Prolactin-induced IRF1 activation in primary monocytes and THP1 cells was examined, with the aim to identify IRF1 interactions with histone acetyltransferases (HATs) and histone deacetylases (HDAC) leading to pathological H4ac in SLE.

Methods:

Flow cytometry for acetylated H4 lysines: K5, K8, K12, K16 were run on the Accuri C6 with isotype controls. H4ac was defined in primary monocytes from 12 normal males under both unstimulated and prolactin-stimulated conditions. Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) evaluated HAT/HDAC expression in monocytes. IRF1 activation by prolactin in primary monocytes was studied by immunofluorescence confocal microscopy. Further interactions of IRF1 and HATs/HDACs were studied in THP1 cells by ChIP analysis.

Results:

Flow cytometry found significantly increased total H4ac, H4K5, H4K8, H4K12, and H4K16 acetylation (p = 0.01, 0.01, 0.01, 0.002, 0.04) in monocytes stimulated at prolactinoma levels (2000 ng/mL); acetylation at total H4ac, H4K5, H4K8, H4K12, and H4K16 was also increased at pregnancy levels (200 ng/mL).

Immunofluorescence showed translocation of IRF1 from the cytoplasm to the nucleus in prolactin-stimulated primary monocytes at both 200 ng/mL and 2000 ng/mL cells by 1 hr, demonstrating IRF1 activation.

qRT-PCR studies of HAT/HDAC expression patterns found increases in PCAF and ATF2 expression monocytes stimulated by prolactin that was dose dependent (p = 0.12 and 0.05). This is comparable to the increase in PCAF expression that was seen in SLE. Additionally, ChIP assays in THP1 cells suggested that prolactin-stimulation can recruit p300 to IRF1 and prolactin target genes.

Conclusion:

These data demonstrate that prolactin stimulation of monocytes induces IRF1 activation and a pattern of acetylated H4 that corresponds to the changes seen in SLE. This helps to explain the known association of prolactinomas with SLE. The identification of candidate HATs that associate with IRF1 in the context of prolactin stimulation may provide for potential therapeutic targets in SLE.


Disclosure: Y. T. Leung, None; K. E. Sullivan, Baxter, 2,Immune Deficiency Foundation, 5,Janssen Pharmaceutica Product, L.P., 5; K. Maurer, None; L. Song, None; L. Shi, None.

To cite this abstract in AMA style:

Leung YT, Sullivan KE, Maurer K, Song L, Shi L. Prolactin Induces Interferon Regulatory Factor 1 Activation and Histone H4 Hyperacetylation in Primary Monocytes Comparable to Changes Seen in Monocytes from Systemic Lupus Erythematosus Patients [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/prolactin-induces-interferon-regulatory-factor-1-activation-and-histone-h4-hyperacetylation-in-primary-monocytes-comparable-to-changes-seen-in-monocytes-from-systemic-lupus-erythematosus-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prolactin-induces-interferon-regulatory-factor-1-activation-and-histone-h4-hyperacetylation-in-primary-monocytes-comparable-to-changes-seen-in-monocytes-from-systemic-lupus-erythematosus-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology